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Abstract. The circumsporozoite antigen of the simian malarial parasite, Plqsmodium 
knowlesi, consists of tandemly repeated immunodominant peptide units which may play a 
role in evading the immune system. To study the immunogenicity of this antigen in the 
absence of the immunodominant repeats, the whole of the non-repetitive region of this 
antigen has been expressed in Escherichia coli. The entire amino-terminal region up to the 
start of the repeats, and the full non-repetitive carboxyl region starting from the end of the 
repeats up to the termination codon, have been expressed separately, as fusion proteins 
with a 26 kD glutathione-S-transferase protein of Schistosomq japonicum. A repeat-less 
truncated antigen has also been expressed as the same fusion protein. The amino-terminal 
fusion protein (GST-CSN), is a soluble protein of a molecular weight of 38 kD, which 
could be purified by affinity chromatography on immobilized glutathione. The carboxyl- 
terminal fusion protein (GST-CSC), is insoluble, migrates with an anomalous molecular
weight of 32 kD, and binds to the affinity matrix weakly. The truncated repeat-less fusion 
protein (GST-CSNC) is also, an insoluble protein of molecular weight of 48 kD. Unlike the 
two separate domains, GST-CSNC is an extremely unstable protein in Escherichia coli.
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1. Introduction 
The major sporozoite surface antigen, the CS-protein, has been implicated as a 
protective antigen in conferring immunity against malaria in a number of animals 
(Nussenzweig and Nussenzweig 1989). The complete nucleotide sequence and the 
deduced protein structure of the CS-gene for a number of species of malarial 
parasites have been documented so far (Kemp et al 1987). In the simian malarial 
parasites, a remarkable diversity in the repetitive region of the CS-genes, is observed 
amongst different strains of the parasite (Sharma et al 1985; Galinski et al 1987). 
The diverse structure of the CS-proteins from two different strains of Plasmodium 
knowlesi, led us to examine the immunogenic cross-reactivity of these antigens 
(Sharma et al 1986). By using various synthetic peptides it was found that multiple 
antigenic sites are present on the CS-antigen (Vergara et al 1985; Sharma et al 
1986). 
The diversity of the repetitive region indicates that it may serve the purpose of an 
immune evasion epitope. Recent reports (Link et al 1990; Schofield and Uadia 1990) 
have shown that the sporozoites elicit a T-cell independent antibody response 
towards the repetitive regions, and it is postulated that this may be to mask the 
adjacent non-repetitive regions of the protein from eliciting an immune response. So 
far the immunogenicity and protectivity of the CS-antigen in the absence of the 
repeat region has not been studied. The immunogenicity of two small stretches of 
amino acids (region I and II), which were found to be conserved in the CS-genes of 
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a number of species, have been assessed using synthetic peptides (Ballou et al 1985, 
Vergara et al 1985). The repeat region of CS-antigens, along with short stretches of 
the non-repetitive parts have been expressed in Escherichia coli before (Young et al 
1985; Barr 1987). The entire CS-gene of P. knowlesi, has been expressed earlier in 
yeast (Sharma and Godson 1985). Recently there has been a report on the 
expression of different regions of the CS-gene of P. falciparum in E. coli as a fusion 
protein of mouse dihydrofolate reductase (Stuber et al 1990). Here we report the 
expression of the entire non-repetitive domains of the CS-antigen of P. knowlesi, as 
fusion proteins in E. coli.
 
2. Materials and methods 
2.1 Construction of the recombinant plasmids 
The construction of the recombinant plasmids for the expression of the two 
domains is shown in figure 1. A 1·4 Kb XmnI fragment of the CS-gene, comprising 
of nearly all of the coding region of the CS-protein, was subcloned from the λKN7 
clone of the Nuri strain (Sharma et al 1985), into the Smal site of plasmid pUC9. In 
all the cloning steps, wherever a blunt-end ligation was performed, the orientation of 
the insert in the resultant plasmid was determined with suitable restriction analysis. 
From this recombinant pUC9 plasmid, a 300 bp BamHI-HpaII fragment of DNA 
coding for the entire amino-terminal region of the protein up to the repeats, was 
filled in and subcloned in the Smal site of the expression system pGEX-3X (Smith 
and Johnson 1988). For the carboxy-terminal region, an RsaI-EcoRV fragment 
from the pKMz plasmid, containing the CS-gene of the H strain (Ruiz et al 1987), 
was introduced at the SmaI site of pUC9 vector. From the recombinant pUC9, the 
 
 
Figure 1. Construction of the recombinant plasmids for the expression of the (A) amino- 
terminal domain, and (B) carboxyterminal domain of the CS-gene. Restriction enzymes: E, 
EcoRV; H, HpaII; Ha, HaeIII; R, RsaI; X, XmnI. The vertical and the oblique bars 
represent the central repeat regions; while the stippled and the unshaded regions depict the 
amino-terminal and the carboxy-terminal non-repetitive regions of the CS-gene, 
respectively. 
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BamHI-EcoRI fragment was subcloned in the expression vector pGEX-2T. The 
difference between the pGEX-3X and pGEX-2T is mainly that in the reading frame 
at the cloning sites. 
The construction of the plasmid for the expression of the repeat-less CS-fusion 
protein is shown in figure 2. The amino-terminal domain was obtained from the 
Nuri strain using XmnI-HpaII restriction, and subcloned in to the Smal site of 
pUC8. A positive clone was selected such that the orientation of the CS-domain 
was the same as the ß-galactosidase gene of pUC8, with the 5'-end towards the 
EcoRI side. The RsaI-EcoRV fragment of the H strain gene, defining the carboxy 
terminal domain was also subcloned in to pUC8, but at the HincII site, which is 
situated 3' to the Smal site of pUC8. From the sequences of the two domains, it 
was assessed that the linker between the Smal and HincII sites would join the two 
fragments in the proper reading frame, provided the orientation of the fragments 
are in the same direction (as the ß-galactosidase gene of pUC8 in this case). The
orientations of the two fragments were determined in the respective pUC8 
recombinant clones, pHX5 and pRRV2 (figure 2) with the help of internal 
restriction site HindiIII. Subsequently, the EcoRI-BamHI fragment of the pHX5 
plasmid containing the amino-terminal domain, was subcloned in to the recipient 
pRRV2 plasmid giving rise to the recombinant plasmid pERP112, containing the 
 
 
Figure 2. Construction of the recombinant plasmid for the truncated repeat-less CS-gene. 
Restriction sites used: B, BamHI; D, DdeI; H, HpalI; Hi, HindIII; Hn, HincII; P, PstI; Pv,
PvuII; R, EcoRI; Rs, RsaI; RV, EcoRV; S, Smal; X, XmnI.
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truncated CS-gene. The EcoRI-PvuII fragment was then subcloned in to pGEX-3X 
for expression. The PvuII site is from the pUC8 plasmid, situated about 200 bp 3'- 
to the termination codon of the CS-gene.
E. coli cells were transformed with the recombinant pGEX plasmids, tested for 
the fusion protein formation, and the positive clones pCSN-18, pCSC-14 and 
pCSNC-32 were identified
 
2.2 Expression and purification of fusion proteins 
E. coli cells transformed with the recombinant plasmids were diluted 1 in 10 from 
overnight cultures into 10 ml of fresh medium and grown for 1 h at 37°C. After 
inducing with isopropyl-D-thiogalactopyranoside (1 mM for pCSN and 5 mM for 
pCSC and pCSNC), they were grown for another 2 h. The cells were pelleted and 
lysed in 1 ml of MTPBS (150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4, pH 
7·3, 1% Triton-X 100). The crude extract was mixed with 100 µl of 50% glutathione
agarose beads (Sigma) and placed on a rotating platform. After absorption for 20 
min, the beads were pelleted and washed repeatedly in MTPBS. The proteins were 
eluted either by boiling in equal volumes of gel loading buffer or by elution with 
5 mM glutathione, and analyzed by SDS-PAGE.
 
3. Results and discussion
The two domains of the CS-antigen that were expressed are shown in figure 1. The 
amino terminal domain was taken from the Nuri strain, as it contained a 
convenient HpaII site at the beginning of the repeat region. This site cuts at the last 
proline residue of the five contiguous conserved amino acids of the region I 
(Sharma et al 1985). The XmnI enzyme restricts at a site 7 bp 3'-to the ATG codon. 
Thus the XmnI-HpaII fragment contained 95 amino acids comprising all of the 
amino-terminal non-repetitive domain of the CS-protein excepting the first three 
amino acid residues. The carboxy-terminal domain was taken from the H strain 
because of the existence of an RsaI site that cuts into the last amino acid of the last 
repeat unit. For expression, a 372 base pair fragment, extending 10 base pair 
beyond the termination codon, containing all of the 121 amino acids of the non- 
repetitive carboxy-terminal region, was used. The same two domains were used in 
the truncated protein construct (figure 2) with a linker region of pUC8, 11 bp from 
Smal site to HincII site, connecting the two. This resulted in the addition of 
aspargine, serine and histidine at the junction of the two domains. The EcoRI- 
PvuII fragment, used for cloning in to the pGEX expression vector (Smith and 
Johnson 1988), contained about 200 bp extra from the pUC8 plasmid. However, 
this extra DNA was situated 3'-to the termination codon of the CS-gene. The 
plasmid pGEX has a glutathione-S-transferase (GST) gene into which the gene 
under study can be cloned, resulting in a fusion protein. The fusion proteins of both 
the carboxy-terminal domain and the truncated protein were terminated at the CS- 
gene termination, while the fusion protein for the amino-terminal domain was 
terminated by the stop codon of the GST protein, provided in all reading frames in 
the pGEX vectors (Smith and Johnson 1988). The plasmids constructed should 
have proper reading frames as assessed from the respective DNA sequences. An 
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incorrect reading frame would result in the termination of the fusion protein after 
20–25 amino acids, as predicted by the sequence (Sharma et al 1985). This would
result in a fusion protein of about 28 to 29 kD. Since the fusion proteins are of 
much higher molecular weight (see below), it is likely that the reading frames are 
proper. 
There is a sequence and hence protein divergence between the Nuri and the H 
strain CS-proteins over 60 base pairs at the end of the repeat region (Sharma et al 
1985). The amino terminal domain on the other hand is 98% conserved between the 
two strains. Thus the two expressed domains, as well as the truncated CS-protein 
virtually represent a subset of the H strain protein.
The GST fusion protein can be induced by IPTG and can be affinity purified to 
> 80% purity by using immobilized glutathione (Smith and Johnson 1988). Figure 
3 shows the production of the amino-terminal fusion protein (GST-CSN) in the 
crude extracts, and after affinity purification. Maximum amounts of protein are 
obtained with 3 h of induction, after which it is saturated. The yield of the fusion 
protein is around 25-30 mg/litre of culture. This protein is soluble, has a molecular 
weight of 38 kD, which is expected from the addition of the 98 amino acids to the 
26 kD GST protein.
 
 
Figure 3. Expression of the amino-terminal region of CS-antigen as a fusion protein. 
Both the panels A and B show a Coomassie stained profile of proteins separated on a 10% 
SDS-PAGE. Panel A: total proteins. Lanes C, R-1 and R-2 are E. coli transformants with 
the pGEX-3X plasmid and two clones for the amino-terminal fusion protein construct, 
containing the insert in the wrong orientation and the correct orientation (pCSN-18), 
respectively. Each lane has protein corresponding to about 0·2 ml of the original culture. 
Panel B: proteins purified on glutathione-agarose beads. Lanes C: Cells transformed with 
vector pGEX-3X; R, recombinant-2 (pCSN-18) of panel A; M, molecular weight markers. 
Cultures were harvested 1 and 3 h after induction. Each lane represents protein from about 
1·5 ml of the original culture. Arrow indicates the fusion protein. I indicates cultures that
were induced with 1 mM IPTG.
 
Figure 4 shows the production of the carboxy-terminal fusion protein (GST-
CSC). The expected molecular weight of this protein is 40 kD, but that observed is
32 kD. To eliminate the possibility of DNA deletion, the size of the insert in pCSC
clone was examined, and was found to be of the appropriate size of 370 bp. Since
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Figure 4. Expression of the carboxy-terminal region of the CS-antigen as a fusion protein 
(GST-CSC). Both the panels A and B show Coomassie stained profiles of proteins 
separated on a 12·5% SDS-PAGE. Panel A: Lanes 1 and 2 are crude extracts of E. coli 
transformed with the control vector pGEX-2T plasmid and the recombinant plasmid 
pCSC-14, respectively. Lanes 3–8 show the distribution of the fusion protein on differential 
centrifugation. Lanes 3 and 4, 600 g pellets; lanes 5 and 6, 16,000 g pellets; lanes 7 and 8, 
supernatants after 16,000 g centrifugation. Odd lanes represent extracts from the control 
cells, while even lanes contain extracts from recombinant cells. Panel B: Purification of 
fusion protein by affinity chromatography on immobilized glutathione. Lane 1, 
recombinant cells; lane 2, control cells. Cultures were grown for 2 h after induction with 
5 mM IPTG. Lanes 1, 2, 7 and 8 contain protein equivalent from 0·2 ml of culture, while 
all the other lanes contain protein from 1·0 ml of culture.
 
several independent transformants showed the same molecular weight for the fusion 
protein (data not shown), the abnormality is unlikely to be due to missense 
mutations arising due to cloning artifacts at the ultimate cloning step for 
expression. However, a missense mutation in the source plasmid cannot be ruled 
out. The anomalous migration of this protein may also be due to the inaccuracy in 
the measurement of molecular weights of membrane proteins (Grefrath and 
Reynolds 1974), or it could be due to some specific proteolytic modification in E. 
coli. Protein degradation during the extract preparation is unlikely to occur in vitro, 
because all preparations have always shown an identical protein band, with no 
evidence of any other lower bands. All CS-proteins have been found to migrate with 
anomalous molecular weights, and it is attributed to its unusual structure 
(Nussenzweig and Nussenzweig 1989).
The GST-CSC protein was found to be largely particulate as shown in figure 4. 
Most of the protein came down with the 650 g and 16,000 g pellets. This protein 
bound to the affinity matrix rather weakly, and perhaps because of its particulate 
nature, pulled down a number of non-specific proteins with it (figure 4B). Maximum 
amount of GST-CSC protein was obtained at 2 h after induction, with lower yield 
of the fusion protein beyond this period of induction. The yield of the GST-CSC 
protein is around 10–15 mg/litre of culture.
Figure 5 shows the expression of the truncated repeat-less CS-protein fused to the 
GST-protein. This protein (GST-CSNC) was found to be extremely labile and the 
induction of the protein was variable. Most of the time the fusion protein could not 
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Figure 5. Expression of the repeat-less truncated CS-gene as a fusion protein. Figure 
shows Coomassie stained profiles of proteins separated on a 10% SDS-PAGE. Panel A: 
Crude extracts; B: 16,000 g pellet; C: 16,000 g supernatant; D: Fusion protein affinity 
purified on glutathione-agarose beads. In each of the panels, lane 1 represents the cells 
transformed with vector plasmid pGEX-3X, while lanes 2 and 3 represent two independent 
culture tubes of the recombinant cells. The arrows indicate the recombinant protein at 
48 kD and the GST-protein at 26 kD. Protein samples are equivalent to: Panels A and C: 
0.15 ml culture; Panel B: 0·3 ml culture and Panel D: 1·5 ml culture.
 
be detected properly in crude extracts. Figure 5 illustrates the behaviour of the 
fusion protein in two independent culture tubes (lanes 2 and 3). In one tube 
containing the recombinant cells (lane 2), the growth was much more than the other 
tube (lane 3), as well as the control cells producing only GST (lane 1); even though 
identical conditions for growth and induction were used. This is an indication of 
non-induction of the fusion protein in this tube (lane 2). Since protein samples 
corresponding to equivalent culture volumes were loaded on the gel, the protein 
content per lane reflects this difference in growth. Not only did the cells in lane 2 
not induce the fusion protein properly, the protein was probably degraded in vivo, 
as most of the fusion protein was found to be degraded to a protein of 26 kD 
molecular weight even in the crude extract, whereas the production of the fusion 
protein in the other tube (lane 3) can be seen distinctly in the crude extract, as well 
as in the 16,000 g pellet, with no evidence of degradation (panels A and B). 
However, after the extra steps for the affinity purification, which takes about an 
hour to perform, even the other recombinant sample shows a considerable amount 
of degradation to a 26 kD protein (lane 3, panel D). The use of certain protease 
inhibitors, to stabilize the fusion protein, did not help significantly. Thus the fusion 
protein appeared to be very unstable both in vivo. and in vitro.
GST-CSNC is also a particulate protein, as most of the protein was found to be
associated with the 16,000 g pellet, rather than the supernatant (figure 5, panels B
and C). The molecular weight of the protein is 48 kD, 4 kD smaller than the
expected molecular weight. Much of the degraded protein is presumably the GST 
protein as a lot of it was recovered in the 16,000 g supernatant as a 26 kD product
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(lane 2, panel C). Since the protein is so labile, it is difficult to estimate the yield 
accurately, but it will be about 5–10 mg/litre of the culture.
It has been difficult to express the entire CS-antigen stably in bacteria (G N 
Godson, personal communications). The instability was thought to be due to the 
repeat region. However, the lability of the GST-CSNC indicates that the lack of 
stability may not be due to the repeat region. Indeed a galactosidase fusion protein 
of the entire CS-antigen of the Nuri strain of P. knowlesi was found to be stable 
(Sharma et al 1986). 
The diversity of the repeat regions of the CS-genes of simian malarial parasites 
implies that the repeat units are not suitable for the use of an effective vaccine. In 
the case of the human malarial parasites, P. falciparum and P. vivax, the repeat 
region was found to be invariant in a number of strains (Arnot et al 1985; Weber 
and Hockmeyer 1985). However, a recent report demonstrates variation in the 
repeat region of over 14% of clinical cases in western Thailand for P. vivax 
(Rosenberg et al 1989). In human and monkey vaccination trials, which were 
conducted using synthetic peptide and recombinant constructs derived from the 
repeat region of the P. falciparum and P. vivax CS-antigens, the success has been 
limited so far (Ballou et al 1987; Herrington et al 1987; Collins et al 1989). 
Furthermore field studies have shown that naturally acquired antibodies against the 
repeat regions, do not provide total protection from infections in persons living in 
malaria endemic areas (Hoffman et al 1987).
Antibodies to the non-repetitive regions of the CS-gene of P. knowlesi have been 
detected earlier in sera of protected monkeys and rabbits immunized with 
sporozoites (Vergara et al 1985; Sharma et al 1986). Some of these epitopes have 
been detected on the surface of the sporozoites and hence are accessible to the 
immune system (Vergara et al 1985). In case of P. falciparum and P. vivax, other B- 
cell epitopes have been detected in the non-repetitive regions (Romero et al 1987; 
Stuber et al 1990). The high expression of the entire non-repetitive domains of the 
CS-protein in E. coil will help in the assessment of the immunogenicity and 
protectivity of these regions, in the absence of the immunodominant immune 
evasive repeat region. Since P. knowlesi and the human malarial parasite P. vivax 
are extremely homologous, it would be of use to assess the protectivity of the P. 
knowlesi non-repetitive regions. 
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